Joanna Shields, BenevolentAI CEO
AI tools don't equal guaranteed drug success as BenevolentAI flops dermatitis test
It’s a no for BEN.
BEN-2293, a topical out of London-based BenevolentAI, has failed secondary efficacy measures in a Phase IIa study in atopic dermatitis. The investigational drug, one of an early generation drummed up by the buzzy AI tools in biotech, works by inhibiting multiple tropomyosin-related kinases, which are known best in the cancer landscape with Bayer’s Vitrakvi and Roche’s Rozlytrek.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters